JAMS decides biotech IP dispute

A JAMS arbitrator has reportedly rejected a California biotech company’s claim that one of its co-founders misappropriated trade secrets relating to developing treatments for neurodegenerative diseases.

Unlock unlimited access to all Global Arbitration Review content